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Abstract
Significance: The management of cancer patients is frequently complicated by the occurrence of a complex syndrome
known as cachexia. It is mainly characterized by muscle wasting, a condition that associates with enhanced protein
breakdown and with negative energy balance. While the mechanisms underlying cachexia have been only partially
elucidated, understanding the pathogenesis of muscle wasting in cancer hosts is mandatory to design new targeted
therapeutic strategies. Indeed, most of cancer patients will experience cachexia during the course of their disease, and
about 25% of cancer-related deaths are due to this syndrome, rather than to the tumor itself.
Recent Advances: Compelling evidence suggests that an altered redox homeostasis likely contributes to cancer-
induced muscle protein depletion, directly or indirectly activating the intracellular degradative pathways. In
addition, oxidative stress impinges on both mitochondrial number and function; the other way round, altered
mitochondria lead to enhanced redox imbalance, creating a vicious loop that eventually results in negative
energy metabolism.
Critical Issues: The present review focuses on the possibility that pharmacological and nonpharmacological
strategies able to restore a physiologic redox balance could be useful components of treatment schedules aimed
at counteracting cancer-induced muscle wasting.
Future Directions: Exercise and the use of exercise mimetic drugs represent the most promising approaches
capable of reinforcing the muscle antioxidant defenses of cancer patients. The results from ongoing and new
clinical trials are needed to validate the preclinical studies and provide effective therapies for cancer cachexia.
Antioxid. Redox Signal. 33, 542–558.
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Introduction
Cachexia is a severe comorbidity of cancer that signifi-cantly complicates patient management, reducing the
tolerance to treatments, worsening the quality of life, and
resulting in about 20% of cancer deaths (4). The consensus
reached some years ago on the definition of cachexia (83)
indicates two main factors as hallmarks of this multiorgan
syndrome: body weight loss, mainly due to fat and muscle
wasting, and chronic inflammation.
The causative mechanisms in the onset and progression of
cancer cachexia are still largely unknown, although in the past
decades, the different contributions of nutrition, reduced anab-
olism, hypercatabolism, and altered energy metabolism have
been shown to play a role (Fig. 1). This picture is further
complicated by the need to treat cancer patients in the attempt to
get rid of the tumor; such treatments are generally very ag-
gressive and by themselves pose several limitations to patient
management, being endowed with significant toxicity (100).
The present review takes into consideration the possible
role played by alterations of the oxidative/reductive (redox)
homeostasis in the pathogenesis of cancer-induced muscle
wasting, as well as the possibility that targeting the redox
balance could be useful to manage this wasting syndrome.
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Mechanisms of Cancer-Induced Muscle Wasting
The depletion of muscle proteins is one of the main fea-
tures of cachexia. It is mainly associated with enhanced
protein degradation rates that can be coupled or not with
reduced protein synthesis. This hypercatabolic response is
mediated by malnutrition and humoral factors, such as
proinflammatory cytokines and hormones, as well as by al-
terations of the energy balance (4). In addition to play a role
in asthenia and weakness, the loss of muscle mass also con-
tributes to the reduced treatment tolerance displayed by many
cancer patients, including the recently achieved immuno-
therapy by checkpoint inhibitors (27).
Being so relevant in terms of patient management, quality of
life, and survival, the evaluation of muscle mass depletion
should be part of the standard protocols in oncology. Despite
this evidence, however, patients do receive a cancer diagnosis
and staging, but very little is done to assess if muscle wasting is
occurring. Indeed, the vast majority of patients are recorded for
body weight or body mass index, without taking into account
body composition and muscle cross-sectional area.
The skeletal muscle comprises the majority of body proteins.
In the adult, muscle mass is maintained fairly constant through
a convergent regulation of protein synthesis and breakdown
rates that in healthy individuals allows the achievement of a
new steady state when the balance is altered. By contrast,
during aging or chronic diseases, breakdown rates generally
exceed those of synthesis, resulting in muscle hypotrophy (91).
All the intracellular proteolytic pathways operating in the
skeletal muscle (proteasome, lysosomes, caspases, and cal-
pains) have been shown to be activated above physiological
levels in cancer cachexia (91). In particular, proteasome and
lysosomes appear those mainly in charge of degrading short-
lived and regulatory proteins, dysfunctional organelles, and
structural proteins (91).
As for lysosomes, their contribution to cancer-induced
muscle wasting mainly reflects the supraphysiological acti-
vation of autophagy, a process by which intracellular material
is sequestered into vacuoles and subsequently degraded upon
vacuole fusion with lysosomes. It occurs physiologically but is
rapidly enhanced by stress conditions such as lack of nutrients/
energy and/or organelle damage. While initially described as
an aspecific degradative process, autophagy has been shown to
be finely tuned to ensure the disposal of specific cargos such as
mitochondria (mitophagy), peroxisomes (pexophagy), bacte-
ria (xenophagy), and lipid droplets (lipophagy) (72).
The possibility to follow the activation of the different
types of autophagy has become feasible due to the discovery
of molecular markers such as Beclin-1, LC3B, p62, Bnip3,
Parkin, and Pink1, the latter three used to detect mitophagy.
Increased autophagic rates have been shown to contribute to
muscle wasting in fasting, aging, denervation, disuse, and
neurodegenerative diseases (91). Similarly, muscle autop-
hagic rates above normal have been reported in experimental
cachexia as well as in cancer patients (8, 95, 97, 132).
However, autophagy induction in cancer cachexia is peculiar
in comparison with other muscle wasting-associated states:
instead of being degraded, autophagosomes do accumulate in
the tissue, probably reflecting lysosomal engulfment and
protease activity exhaustion (95). Consistently with these
observations, both inhibition and overstimulation of autop-
hagy are detrimental in tumor-bearing mice (92, 95).
The second relevant proteolytic system in the muscle is
that dependent on proteasome. This mainly acts on regulatory
and/or damaged proteins targeted for degradation by ubi-
quitylation, operated by three different classes of enzymes,
namely E1, E2, and E3. In particular, the E1 group includes
enzymes able to activate ubiquitin, and E2s conjugate ubi-
quitin to the protein substrate, while E3s are ubiquitin ligases.
The latter are endowed with tissue/substrate specificity.
FIG. 1. Cancer cachexia
is a multifactorial syndrome.
The underlying mechanisms
in the onset and progression
of cancer cachexia are still
largely unknown, however,
tumor-induced alterations as
well as anticancer treatments,
directly or indirectly, impinge
on lipid, protein, and energy
metabolism. The cross talk
among tissues also plays a
role in impairing muscle
anabolism, inducing hyper-
catabolism and altering en-
ergy metabolism, eventually
leading to muscle atrophy,
the most relevant feature of
cancer cachexia.




















































Along this line, there are several muscle-specific E3s:
atrogin-1 and MuRF1, the first to be identified, MUSA1,-
TRIM32, TNF receptor-associated factor (TRAF)6, and
SMART (63). Muscle-specific E3s are currently used as
molecular markers of proteasome-dependent proteolysis. In
this regard, their increased expression has been shown in
several conditions associated with muscle wasting, including
cancer cachexia (4), although contradictory results have been
reported (88, 132).
Despite lysosomes and proteasome appear overactivated in
conditions associated with muscle wasting, they are unable to
directly break down myofibrillar proteins. To become avail-
able for degradation, the latter should undergo a preventive
cleavage likely operated by calpains and/or caspases (91),
whose activity in the muscle is indeed upregulated in both
tumor-bearing animals (29, 71, 101) and cancer patients (124).
The enhanced protein turnover that occurs in muscle
wasting can also reflect reduced protein synthesis rates.
However, in cancer cachexia at least, this is not a definite
finding, since muscle protein synthesis has been reported to
increase, decrease, or remain unchanged (4). Data obtained
studying experimental model systems have provided con-
trasting information: reduced protein synthesis has been ob-
served in mice hosting the C26 or the Lewis lung carcinomas
(LLC) (9, 87, 136), while normal anabolic potential has been
shown by rats bearing the Yoshida AH-130 hepatoma (30).
The situation is far from being clear also in cancer patients.
While there are studies reporting a reduction of muscle protein
synthesis (42, 55), improvement of baseline synthetic rates has
been shown to occur in pancreatic cancer patients (36).
Another relevant mechanism impinging on muscle wasting
in cancer cachexia is the early alteration of energy metabo-
lism. In this regard, most of the cancer patients are charac-
terized by resting energy expenditure (REE) increased in
comparison with the normal population (141). Of interest, a
significant number of patients considered hypermetabolic do
not report loss of body weight and are characterized by good
performance status (141). The lack of correlation between
body weight loss and hypermetabolism is also confirmed by
another study performed on bladder cancer patients, showing
that the recovery after surgery is faster for metabolic rates
than for body weight loss (135).
Hypermetabolism in cancer patients is likely driven by
molecules released by the tumor and/or by the organism in
response to tumor growth. The possibility that large tumors
drain energy, producing a sort of stripper action against the
organism, is not particularly sounding. Indeed, tumor mass in
cancer patients is generally low in comparison with body
weight (106).
Alterations in thermogenesis, the process in charge of heat
production, also contribute to increase REE in cancer pa-
tients. It mainly occurs in the skeletal muscle (shivering
thermogenesis) and in the brown adipose tissue (BAT; non-
shivering thermogenesis). The former modality of heat pro-
duction is characterized by low metabolic efficiency and is
generally rapidly activated when the organism faces heat loss
due to cold exposure. By contrast, the adaptation to a cold
environment is more effectively achieved by activating the
nonshivering thermogenesis. In addition to cold exposure,
also meal ingestion stimulates thermogenesis in the BAT at
an extent that depends on meal size and composition, as well
as on the action of the sympathetic nervous system, mainly
exerted by norepinephrine release. Both skeletal muscle and
BAT are characterized by high expression of uncoupling
proteins (UCPs), which are involved in the dissipation of the
proton gradient in mitochondria, resulting in energy loss that
is used to produce heat rather than ATP. Consistently with the
occurrence of hypermetabolism, increased expression of
UCPs with respect to control values has been reported in both
tumor-bearing animals and cancer patients (14, 26).
The presence of the tumor is also associated with a phe-
nomenon defined as ‘‘browning,’’ characterized by the con-
version of white adipocytes into brown adipocyte-like cells.
This process contributes to cancer-induced fat depletion and
increased REE by shifting energy from ATP to heat pro-
duction (4). Of interest, both browning and increased REE
have been associated with increased expression of the tumor-
derived parathyroid-hormone (PTH)-related protein, whose
knockdown confers resistance to cancer-induced cachexia in
experimental models (65, 66). These observations confirm
the existence of a cross talk between fat and muscle (4).
Consistently, genetic deletion of the adipose triglyceride li-
pase (33) or treatment with the fatty acid oxidation inhibitor
etomoxir (48) has been shown to prevent cancer-induced
muscle wasting in mice.
The increased REE in cancer patients is associated with
decreased energy production that mainly derives from re-
duced food intake and from the activation of futile metabolic
cycles that divert energy from storage to wasting. In addition
to these rather obvious explanations, in the last decade, the
idea that something wrong likely occurs to the energy pro-
duction machinery in mitochondria is gaining a growing
consensus.
Along this line, ultrastructural and functional changes have
been observed in muscle mitochondria in tumor-bearing an-
imals (47, 99, 122), ultimately resulting in impaired oxidative
capacity (61, 138) and, by activating mitophagy, in reduced
mitochondrial number. Other studies have reported the oc-
currence of alterations in mitochondrial fusion, fission, and
biogenesis (see also the Mitochondria as Pivotal Elements in
Muscle Oxidative Stress section), frequently associated with
a proinflammatory environment (9, 148). Cancer-related ef-
fects on muscle mitochondria also affect the ability of the cell
to maintain the physiological redox balance that is frequently
disrupted in favor of the oxidative arm (see Role of Oxidative
Stress in Muscle Wasting and Dysfunction section).
Role of Oxidative Stress in Muscle Wasting
and Dysfunction
Oxidative stress is caused by the accumulation of the
physiologically produced reactive oxygen or nitrogen species
(ROS/RNS). ROS increase can derive from increased pro-
duction or decreased antioxidant capacity, due to low con-
centration of molecules endowed with antioxidant properties
and/or impaired activity of the antioxidant enzymes (3). At
physiological concentrations, ROS regulate distinct signaling
pathways, mainly activating mitogen-activated protein ki-
nases (MAPKs) such as ERK and JNK and inhibiting the
phosphatase calcineurin, leading to the nuclear translocation
of transcription factors involved in cell proliferation, differ-
entiation, survival, or in the regulation of intracellular protein
turnover (102). On the contrary, excessive ROS/RNS levels
result in modification of DNA, proteins, and lipids such as




















































nitration, nitrosylation, carbonylation, and glycation, causing
cellular dysfunction and potentially leading to cell death,
according to the magnitude of the oxidative insult.
The bimodal response to ROS fits with the hormesis the-
ory, based on the concept that the exposure to low levels of a
damaging agent may induce an adaptive response able to
‘‘train’’ the cell to properly respond to a subsequent dam-
aging stimulus of enhanced intensity (59). Adapting the
concept to the redox status, a transient oxidative stress re-
flects a potentially beneficial adaptation process, while an
uncontrolled accumulation of ROS/RNS leads to pathologi-
cal cellular damage.
The importance of oxidative stress in modulating muscle
mass and function was highlighted many years ago studying
age-related sarcopenia. Indeed, the activity of antioxidant
enzymes decreases with age and similar results have been
obtained in several chronic pathological conditions (81). As
any other cell type, muscle fibers counteract ROS activity at
different levels: (i) prevention of ROS-generating mito-
chondrial electron leakage; (ii) ROS scavenging by enzymes
of the detoxification pathway, including superoxide dis-
mutase (SOD), catalase, glutathione peroxidase (GPX), and
peroxiredoxin; and (iii) ROS neutralization with antioxidant
molecules such as reduced glutathione and vitamins C and E.
The cellular antioxidant capacity is stimulated by low ROS
levels that promote an adaptation mechanism leading to in-
creased expression of the detoxifying enzymes and accumu-
lation of antioxidant molecules (see the Exercise Counteracts
Cachexia Modulating the Redox Homeostasis section for
further details). Among the signaling regulatory factors that
sense intracellular ROS, the nuclear factor-kappaB (NF-jB),
the activator protein-1 (AP-1), the heat shock transcriptional
factor-1 (HSF-1), and the nuclear respiratory factor (Nrf)2
regulate several muscle homeostatic processes and trigger the
increased expression of antioxidant enzymes (84).
In cancer-induced muscle wasting, the status of the anti-
oxidant defense is not univocally defined. The reduction of
most antioxidant enzyme expression and activity coupled
with increased superoxide levels has been reported in the
muscle of cachectic mice bearing the MAC16 tumor (130).
Similar observations have been confirmed in patients affected
by distinct cancers, either weight stable or weight losing,
suggesting that the loss of the antioxidant defense is more
related to the presence of a tumor rather than to the loss of
muscle mass (19).
By contrast, a preclinical study has shown that cachexia
induced in the host rat by the AH-130 tumor leads to distinct
responses in locomotor and respiratory muscles, the former
being more susceptible to oxidative stress than the latter,
despite the increase of the endogenous antioxidant defense
(115), likely due to an ineffective adaptive response. Simi-
larly, increased pro-oxidant species coupled with the acti-
vation of the antioxidant defense has been reported in the
muscle of C26-bearing mice (6, 12). These observations are
supported by data obtained in the quadriceps muscle of lung
cancer patients, suggesting that tumor growth does not halt
the adaptive antioxidant muscle response (104), although it
might be insufficient to cope with the magnitude of the oxi-
dative insult.
When ROS accumulation exceeds the adaptation capacity
of the cell, several molecular pathways are activated, even-
tually leading to muscle atrophy and/or dysfunction (Fig. 2).
As described above (see the Mechanisms of Cancer-Induced
Muscle Wasting section), muscle wasting results from the
imbalance between protein synthesis and degradation, the
latter overpassing the former. High oxidative stress can
directly or indirectly modulate both the protein synthe-
sis machinery and the degradation pathways. Indeed,
ROS are known modulators of the phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K)/Akt/mTORC1 pathway, the
main intracellular regulator of protein synthesis (131).
As for the protein degradation machinery, ROS excess can
alter calcium homeostasis, which in turn activates the cys-
teine protease calpain leading to myofilament release (77). In
parallel, calcium dysregulation might promote aberrant NF-
jB activity triggering the simultaneous activation of distinct
proteolytic systems (118). Beyond the calpain system, se-
vere muscle wasting is generally associated with the hyper-
activation of the degradation systems responsible for
the disposal of bulk proteins and organelles, namely the
FIG. 2. Mechanisms of
oxidative stress-induced
muscle wasting. ROS/RNS
imbalance, due to insufficient
muscle cell adaptation, di-
rectly and indirectly generate
distinct intracellular ‘‘Sig-
nals’’ that in turn activate
‘‘Effector’’ proteins/systems
eventually leading to most





tion; ox-stress, oxidative stress;
RNS, reactive nitrogen species;
ROS, reactive oxygen species.




















































ubiquitin/proteasome and the autophagy systems. As for the
former, a direct link with the oxidative stress has been sug-
gested by in vitro observations on C2C12 myotubes, where
the exposure to H2O2 results in increased enzymatic activity
and expression of proteasome components (51).
In addition, a recent study has shown that diaphragm at-
rophy occurring during mechanical ventilation depends on
ROS-induced proteasome and autophagy activation (80). In
this regard, the occurrence of a cross talk between oxidative
stress and autophagy has been previously suggested by ob-
servations reporting that blocking mitochondrial ROS pro-
duction using the antioxidant SS-31 in rats exposed to
mechanical ventilation improves both increased autophagy
and muscle wasting (126). Beyond inactivation of the PI3K/
Akt/mTORC1 and activation of the FOXO pathways, ROS-
induced autophagic degradation in the skeletal muscle was
proposed to rely on both p38 MAPK and the energy sensor
AMP-activated protein kinase (AMPK) (109).
In addition to proteasome and autophagy, oxidative stress
also results in activation of caspases. Indeed, caspase-3 has
been reported to be activated by ROS in the diaphragm upon
mechanical ventilation (76, 126). Caspase-3 has been linked
to protein depletion in cancer cachexia (123), despite its ac-
tivation being generally associated with apoptotic cell death.
In this regard, ROS-induced loss of myogenic cells or cellular
senescence has been suggested to be relevant in the onset of
aging-related sarcopenia, such mechanism being also ROS
and autophagy dependent (49, 127). Dysregulation of myo-
genesis has been reported to contribute to the onset of cancer-
induced muscle wasting (56, 94), with a mechanism that
involves excessive ERK or NF-jB activation. Of interest, both
signaling pathways could be stimulated by local oxidative
stress, although such hypothesis has not been tested, so far.
Finally, it is worthy mentioning that, beyond muscle
quantity, oxidative stress might also affect muscle quality,
that is, the ability to produce workload. Consistently, quality
of life in cancer patients is frequently worsened by the oc-
currence of fatigue. From the cellular and molecular point of
view, most of the ROS-induced alterations affecting muscle
quality have been studied in aged individuals or rodents, sug-
gesting that ROS interfere with the neuromuscular junction
functionality, with the excitation/contraction (EC) coupling at
the ryanodine receptor (RyR), and with the cross-bridge cycling
in the sarcomere (13). The oxidative stress-induced degenera-
tion of the neuromuscular junction was demonstrated in mice
lacking the antioxidant enzyme SOD (58) and is now con-
sidered a relevant alteration associated with muscle wasting
(113), linking oxidative stress, muscle wasting, and func-
tional impairment.
Mitochondria as Pivotal Elements
in Muscle Oxidative Stress
The skeletal muscle accounts for about 40% of the body
mass. It requires large amounts of oxygen for contraction, but
even at rest it is responsible for more than 20% of body
oxygen consumption (153). Such elevated respiration implies
that the muscle can generate a relevant quantity of ROS,
however, the magnitude of ROS production only partly relies
on the amount of oxygen consumed, being highly dependent
on mitochondrial ‘‘health’’ or quality. Mitochondria are an
interconnected and very dynamic network able to adapt to the
metabolic requirement of the cell/tissue. When a damaging
insult occurs, the mitochondrial network undergoes degen-
eration, eventually leading to loss of mitochondrial ATP
production and to dramatic increase of ROS release (68).
The maintenance of mitochondrial quality requires a class
of proteins involved in the so-called mitochondrial quality
control, taking care of the mitochondrial network health
(112). Briefly, these proteins are involved in mitochondrial
turnover, on one hand regulating the biogenesis of new mi-
tochondria and their fusion to incorporate them in the elon-
gating network, and on the other hand, the fission of the
dysfunctional mitochondrial domains from the network and
the degradation through the autophagy system, specifically
defined ‘‘mitophagy.’’ The altered expression of the proteins
involved in each of these processes has been causally linked
to the regulation of oxidative stress and muscle mass (Fig. 3).
FIG. 3. Impaired mito-
chondrial homeostatic pro-
cesses drive muscle wasting
and oxidative stress. Mi-
tochondrial biogenesis, fu-
sion, fission, and degradation
(mitophagy) are regulated by
specific proteins that, beyond
impacting on energy metab-
olism, modulate oxidative
stress and are in turn affected
by ROS, potentially modulat-
ing muscle mass and function
during cachexia. The figure
depicts the most studied pro-
teins regulating such pro-
cesses, the impact on oxidative
stress, antioxidant defenses,
energy production, muscle
mass, and the known modula-
tion during cancer cachexia.
KO, knockout.




















































Mitochondrial biogenesis mainly depends on the activity
of the transcriptional coactivator PGC-1a that promotes the
activity of transcription factors critical for the synthesis
of mitochondrial components (105). In the heart, PGC-1a
is required for the induction of the antioxidant defense,
triggering the expression of SOD2 and thioredoxin (73). In
addition, PGC-1a muscle expression is impaired in tumor-
bearing animals and further reduced upon chemotherapy
administration (9). The same work has demonstrated that
muscle PGC-1a overexpression is not able to spare cancer-
and chemotherapy-induced muscle depletion, distinctly from
denervation and fasting where PGC-1a has proven sufficient
to rescue muscle mass (117). The higher mitochondrial
content and PGC-1a expression of oxidative fibers (70) as-
sociate with increased antioxidant defenses when compared
with glycolytic fibers, having a lower mitochondrial load
(22). The observation that oxidative fibers are less susceptible
to cancer-induced atrophy (25) points to a relationship among
fiber metabolism, oxidative stress, and wasting, suggesting
that the antioxidant and metabolic properties of oxidative
fibers should be preserved to spare muscle mass.
Beyond mitochondrial biogenesis, also the mitochondrial
fusion process, which along with fission is generally de-
scribed as mitochondrial dynamics, has been recently in-
volved in the regulation of muscle mass. The fusion
machinery is composed by mitofusin (Mfn)1 and 2, involved
in the fusion of the outer mitochondrial membrane and optic
atrophy protein 1 (Opa1), required for the fusion of the inner
membrane (112). Muscle-specific Mfn2 ablation causes the
appearance of an aged phenotype characterized by massive
ROS accumulation and impaired muscle mass and function
(120). Consistently, Mfn2 deficiency was described in ex-
perimental (9, 150) and human cancer cachexia (75, 150).
The overexpression of Mfn2 was sufficient to counteract
skeletal muscle wasting in mice bearing the HCT116 tumor
(150). Similarly to Mfn2, muscle Opa1 loss leads to severe
disruption of the mitochondrial network with marked muscle
atrophy and an aged phenotype (110, 133).
Opposite to fusion, fission produces a fragmented mito-
chondrial network. Contributing to the latter, the dynamin-
related protein 1 (Drp1) interacts with protein receptors
bound to the outer mitochondrial membrane, namely Fis1 and
Mff (112). Regarding the role of mitochondrial fission in the
onset of muscle atrophy, there are scanty and conflicting data.
Fis1 protein levels have been reported to be upregulated in
cachectic cancer patients (75), while both Fis1 and Drp1 gene
expressions are downregulated in mice bearing the C26 tumor
(9, 92). Also, the genetic manipulation of fission-related
genes has produced contrasting data. On one hand, muscle-
specific Drp1 deletion has been associated with muscle
wasting and weakness (44), while Fis1 knockdown is pro-
tective against fasting-induced myofiber atrophy (111).
These data could be reconciled keeping in mind the
hormesis theory, thus considering that basal fission activity
is essential for the maintenance of muscle health, while
excessive fission induces muscle wasting.
The final step of mitochondrial turnover is degradation
through mitophagy. Dysfunctional or damaged mitochondria
are recognized by the lysosomal/autophagic system when
tagged with specific proteins, such as the Pink1/Parkin
complex that triggers the ubiquitylation of several mito-
chondrial substrates, including Mfn2 (24) or Bnip3 that binds
to the autophagosome membrane protein LC3B (40). Keep-
ing in mind that oxidative stress is highly dependent from
mitochondrial health, an increased ROS production from
mitochondria also turns into a mitochondrial damaging in-
sult, enhancing the oxidative stress and triggering mitophagy.
In this regard, in cachectic muscles, a feed-forward mecha-
nism has been postulated, in which oxidative stress-induced
mitochondrial damage triggers mitophagy, impairing mito-
chondrial activity and abundance, eventually activating the
catabolic pathways responsible for muscle wasting (144).
Such mechanism finds confirmation from recent works
showing that oxidative stress and mitochondrial degeneration
are an early event that precedes muscle wasting in mice
bearing the LLC tumor (18). Similarly, mitophagy induced
by C26 tumor growth impairs mitochondrial respiratory
function and forcing autophagy in cachectic mice exacer-
bates mitophagy and consequently muscle protein depletion
(92). Consistently, increased expression of markers of au-
tophagy and mitophagy has been detected in muscle biopsies
from cachectic cancer patients (8).
Mitochondrial oxidative stress, leading to impaired mito-
chondrial function and abundance, does not only imply the
activation of muscle protein catabolism but even more im-
portantly affects the metabolic properties of the muscle as
well, producing a systemic energy failure and worsening
patient fatigue. The impairment of mitochondrial oxidative
capacity triggers a metabolic shift of the myofibers from
oxidative to glycolytic (99), reducing the ability to produce
ATP (9, 138). Both cancer and chemotherapy were shown to
interfere with muscle oxidative metabolism. Indeed in C26-
bearing mice or in mice exposed to chemotherapy, severe
oxidative stress was coupled with a dramatic reduction of the
tricarboxylic acid cycle and b-oxidation flux, producing an
increased glucose demand that requires both glucose and
glycogen mobilizations from the liver (69, 98).
Inflammation and Oxidative Stress Cross Talk
in the Muscle and Beyond
As reported above, chronic inflammation is one of the
hallmarks of cancer cachexia. In this regard, high circulating
levels of acute-phase mediators, C reactive protein in par-
ticular, and increased production of proinflammatory cyto-
kines such as tumor necrosis factor (TNF)a, TNF-like weak
inducer of apoptosis (TWEAK), TRAF6, interleukin (IL)-1,
IL-6, and interferon (IFN)c have been reported in cancer
patients (5). In addition, mice hosting the C26 tumor show
increased expression of messenger RNAs (mRNAs) coding
for acute-phase proteins in the skeletal muscle (16). The other
way round, there are studies showing that cachexia is associ-
ated with reduced expression of anti-inflammatory cytokines
such as IL-10 (28). Finally, the association between cachexia
and polymorphisms on genes coding for IL-8, IL-10, and TNFa
has been reported in cancer patients (15, 34, 103).
Several lines of evidence demonstrate that proin-
flammatory cytokines contribute to cachexia. In healthy an-
imals they induce loss of both muscle and adipose tissue
mass, an effect dependent on the ability of these mediators to
negatively affect protein and lipid anabolism, stimulating
catabolism (134). Indeed, enhanced protein turnover rates
associated with lipolysis, reduced activity of the lipoprotein
lipase, and induction of the hormone-sensitive lipase have




















































been reported upon cytokine administration to experimental
animals (5). Of interest, tumor hosts frequently show com-
parable alterations that, in experimental settings at least, can
be prevented by treating the animals with specific anti-
cytokine antibodies (5).
Proinflammatory cytokines significantly contribute to the
pathogenesis of cancer cachexia. They mainly act through
signaling pathways dependent on NF-jB and p38 MAPK.
Both of them contribute to increase the expression of muscle-
specific ubiquitin ligases such as atrogin-1 and MuRF1,
eventually resulting in muscle protein hypercatabolism (5).
Consistently, inhibition of NF-jB transcriptional activity has
been shown to protect against cancer-induced muscle wasting
(79). In addition, proinflammatory cytokines can result in
peripheral insulin resistance, impacting on the signal trans-
duction pathways downstream the insulin receptor. Similarly,
TNFa negatively impinges on the bioactivity of the insulin-
like growth factor (IGF)-1, impairing tissue anabolism and
stimulating catabolism (134). In some experimental models,
cachexia is associated with increased expression of TWEAK
that results in enhanced MuRF-1 levels and autophagy (67).
Particularly intriguing is the observation that cytokines pro-
duced by different tissues for different reasons may eventually
target the skeletal muscle, eliciting a wasting response. This
applies, for example, to transforming growth factor (TGF)b
released from bone metastasis, proposed as a significant con-
tributor to muscle wasting (147). In this regard, TGFb can
negatively regulate skeletal muscle mass by impinging on the
Smad2/3 transcription factor complex, resulting in muscle
wasting due to enhanced myostatin/activin signaling (23). An-
other mechanism by which both TGFb and TNFa may mediate
cachexia is the induction of the zinc transporter ZIP14, resulting
in loss of myosin heavy chain in the adult muscle (146).
Together with mitochondrial alterations, supraphysiolo-
gical levels of proinflammatory cytokines are among the
main contributors to the disrupted redox homeostasis in
cachexia. In this regard, the first evidence that ROS/RNS and
inflammation are strictly interconnected is a rather old one
(96). Subsequently, the discovery that at least some of the
canonical proinflammatory cytokine-driven transcription
factors such as NF-jB, AP-1, and Nrf2 can be regulated by
the redox balance has clearly defined the relationship oc-
curring between inflammation and oxidative stress. In this re-
gard, ROS/RNS can activate redox-sensitive transcription
factors, leading to the overexpression of both antioxidant mol-
ecules and proinflammatory cytokines. The latter further induces
the production of oxidative species, feeding a vicious circle that
amplifies the effects exerted by oxidative stress and inflamma-
tion on muscle protein and energy metabolism (Fig. 4). Along
this line, TNFa has been shown to stimulate ROS production by
mitochondria as well as by activating NADPH oxidase and
xanthine oxidase, releasing high O2
- levels that are rapidly
dismutated to H2O2 (1, 139). Accumulation of the latter in the
muscle results in stress of the sarcoplasmic reticulum, altering
the intracellular calcium homeostasis and likely impinging on
the regulation of intracellular proteolysis by activating calpains
(see also Role of Oxidative Stress in Muscle Wasting and
Dysfunction section).
In addition, H2O2 can activate both NF-jB and Smad3, on
one hand enhancing the inflammatory response, and on the
other hand, further contributing to muscle protein hyperca-
tabolism by inducing the transcription of genes coding for
muscle-specific ubiquitin ligases and autophagy (see above)
(7). Additional observations show increased O2
- levels in the
muscle of tumor-bearing mice, associated with decreased
expression of two NADPH oxidase subunits, and also of
SOD1/2 and GPX, underlying the relevance of the antioxi-
dant machinery to the maintenance of redox homeostasis (1).
Increased oxidative stress in the skeletal muscle has been
shown to occur upon exposure to TGFb derived from
bone resorption induced by osteolytic metastasis. Indeed, by
inducing the expression of NAPDH oxidase 4, TGFb causes
an increased ROS production, resulting in oxidation of
RyR1 and in calcium homeostasis disruption, ultimately
FIG. 4. Reciprocal inter-
action between inflamma-
tion and oxidative stress.
Proinflammatory cytokines
and ROS and RNS target the
same transcription factors in
skeletal muscle cells. This
results in enhanced protein
breakdown rates and increased
cytokine synthesis. The latter
further contributes to produce
ROS/RNS, giving rise to a
vicious circle that overcomes
the intracellular antioxidant
defense.




















































contributing to muscle wasting. Consistently, NADPH oxi-
dase 4 expression is reduced by treatments able to interfere
with TGFb release or signaling (2, 147). Finally, the analysis
of secretome from cancer cells has highlighted the release of
a huge number of proinflammatory mediators that markedly
enhance fatty acid oxidation in the skeletal muscle, leading to
oxidative stress and tissue protein depletion (48).
Exercise Counteracts Cachexia Modulating
the Redox Homeostasis
Exercise training is a nonpharmacological and cost-
effective tool adopted for preventive and therapeutic pur-
poses in different pathologic conditions and aging (143). The
effects of exercise include increased muscle fitness and car-
diovascular, metabolic, and psychological improvements
(21, 41, 46). Notably, one of the mechanisms by which
physical training affects muscle mass and function may rely
on the regulation of the redox homeostasis (1). The beneficial
effects of modulating the redox balance by exercise could
again be explained by hormesis (see the Role of Oxidative
Stress in Muscle Wasting and Dysfunction section) (59).
Indeed, exercise is able to induce a transient increase of ROS
production, resulting in the activation of different metabolic
pathways according to the intensity and type of exercise (59).
Whereas regular and nonstrenuous exercise leads to low
ROS production inducing metabolic adaptations poised to
improve muscle function, strenuous exercise leads to exces-
sive ROS levels, resulting in muscle damage (119). Among
the adaptations induced by regular exercise, the reduction of
systemic inflammation, the improvement of mitochondrial
function, and the increase of the antioxidant defenses play a
pivotal role in modulating the muscle redox homeostasis (84,
116), producing a potentially anticachexia response.
As described above, cachectic animals show impaired re-
dox balance, likely affecting muscle metabolism (7). In this
regard, physical exercise has proven effective in counter-
acting some of the redox alterations observed in tumor hosts.
The improvement of muscle mass and function induced by
moderate exercise in C26 tumor-bearing mice has been as-
sociated with improved oxidative stress, increased expression
of antioxidant enzymes, and restoration of Nrf2 signaling
(12). Since oxidative stress may also stimulate the proteolytic
systems, the partial normalization of the redox homeostasis in
the skeletal muscle of tumor-bearing mice might explain the
reduction of autophagy, as suggested by the rescue of LC3B
and p62 protein levels (12). Similarly, exercised rats bearing
the Walker-256 tumor have shown a reduction of MDA levels
coupled with the restoration of the GSH/GSSG ratio (89).
These findings have been associated with a reduction of
systemic inflammation, as shown by reduced levels of
proinflammatory cytokines such as IL-6 and TNFa and by
increased concentrations of the anti-inflammatory IL-10 (89).
Bearing in mind that inflammation activates a signaling
cascade leading to ROS/RNS production and oxidative stress
(see the Inflammation and Oxidative Stress Cross Talk in the
Muscle and Beyond section), exercise could be considered an
anti-inflammatory agent (50) even in cancer cachexia. In this
regard, several studies concerning cancer cachexia have
demonstrated that exercise may reduce the production of
different proinflammatory factors (39, 90, 99), likely con-
tributing to reduce oxidative stress and muscle wasting.
Similar observations have been reported in cancer patients, in
which physical training decreases markers of oxidative stress
in the blood while increases the antioxidant capacity, re-
sulting in reduced fatigue (108).
Beyond counteracting the detrimental effects of tumor
growth, exercise is also effective in decreasing the oxidative
stress induced by chemotherapeutic agents, the latter con-
tributing to fatigue and reduced mobility in cancer patients
(100). In this regard, several lines of evidence have shown
that exercise is able to correct doxorubicin-induced cardiac
alterations by modulating the redox balance. Notably, an
acute bout of exercise decreases lipid peroxidation products,
improving the cardiac function in rats treated with doxoru-
bicin (149). Similarly, 8 weeks of aerobic exercise protect
doxorubicin-treated mice from cardiac injury, decreasing 4-
HNE-protein adduct in plasma and heart while increasing
heart MnSOD levels (38).
The increased oxidative stress induced by doxorubicin is
prevented by exercise also in murine skeletal muscle, re-
ducing protein carbonylation and 4-HNE accumulation
(125). Such pattern associates with reduced calpain/calpas-
tatin ratio, calpain activity, and caspase-3 levels and activity
(125). Consistently, another study has reported that aerobic
exercise reduces the levels of markers of oxidative stress
and increases MnSOD levels in heart mitochondria of
doxorubicin-treated mice, resulting in increased mitochon-
drial content and oxidative function (74). However, exercise
effectiveness in reverting oxidative stress is limited, in par-
ticular when tumor growth is combined with chemotherapy
administration, resulting in severe muscle wasting. In this
regard, moderate exercise, although being able to partially
spare muscle mass and loss of function, does not correct
the increase of ROS levels and protein carbonylation in
chemotherapy-treated tumor-bearing mice (9).
Exercise may also affect the muscle redox balance mod-
ulating mitochondrial function (59). As described in the
Mitochondria as Pivotal Elements in Muscle Oxidative Stress
section, mitochondrial homeostasis is severely impaired in
the skeletal muscle of cachectic subjects, leading to increased
ROS production that in turn leads to mitochondrial damage in
a vicious cycle (32). In this regard, exercise modulates mi-
tochondrial homeostasis impinging on biogenesis, function,
and disposal, likely contributing to improve mitochondrial
fitness and reducing oxidative stress (84), see Figure 5.
As previously discussed, one of the central regulators of
the exercise-induced mitochondrial adaptations is the co-
transcriptional factor PGC-1a. Beyond the regulation of the
mitochondrial biogenesis, PGC-1a induces the activation of
the antioxidant defenses (60). Consistently, the ablation of
PGC-1a blunts some of the effects induced by exercise
training in the skeletal muscle (11), and reduces the levels of
different antioxidant enzymes (54). The other way round,
PGC-1a overexpression in the tibialis anterior muscle de-
creases oxidative stress while increasing the antioxidant de-
fenses in a model of immobilization-induced muscle atrophy
(62). Consistently, some of the protective effects of exercise
against muscle wasting may rely on the induction of PGC-1a.
In this regard, several reports have demonstrated that exercise
is able to induce the expression of this cotranscriptional
factor in cancer cachexia. Notably, together with the reduc-
tion of markers of oxidative stress and increased antioxidant
defenses, moderate exercise in C26-bearing mice increases




















































PGC-1a levels and mitochondrial content (12). Similarly,
PGC-1a expression increases in the C26 hosts upon com-
bined exercise, including both aerobic and resistance training
(107), and in chemotherapy-treated C26-bearing mice ex-
posed to moderate endurance exercise (9). The increase of
PGC-1a levels upon exercise training has been observed also
in ApcMin/+ mice (148) and in C26 and LLC hosts, receiving
also erythropoietin (EPO) or eicosapentaenoic acid (EPA),
respectively (93, 99).
Together with the induction of mitochondrial biogenesis,
exercise modulates mitochondrial fusion/fission events and
mitophagy, thus regulating mitochondrial quality and function
in the skeletal muscle (60). As reported above, the impairment
of one of these events could lead to the accumulation of
damaged mitochondria and oxidative stress. In aging, aerobic
exercise increases the expression of mitochondrial protein
related to both mitophagy and dynamics (64). Similarly, the
effect of exercise training in tumor-bearing animals is poised
toward the normalization of autophagy/mitophagy and mito-
chondrial fusion and fission. In this regard, the increase of
Bnip3 levels is corrected by the combination of exercise and
EPO administration to tumor hosts, coupled with reduced
mitochondrial alterations and increased function (99). In
chemotherapy-treated tumor-bearing mice, exercise increases
Mfn2 gene expression, together with decreased Bnip3,
PINK1, and Parkin levels (9). Similarly, a report by White
et al. has shown that exercise increases Mfn2, while de-
creasing Fis1 protein expression in the skeletal muscle of
ApcMin/+ upon IL-6 overexpression (148).
Potential Impact of Antioxidants and Exercise
Mimetics in Cancer Cachexia
An intuitive way to reduce oxidative stress is the admin-
istration of exogenous antioxidants able to scavenge ROS/
RNS, such as vitamins, carotenoids, and polyphenols. How-
ever, the studies concerning the use of this type of compounds
in cancer growth and treatment, as well as in cancer cachexia,
have produced controversial data. Although some antioxi-
dants seem effective in reverting cancer-induced muscle
wasting by reducing inflammation and oxidative stress (7, 17),
other studies underline that antioxidants may promote tumor
growth and reduce radio/chemotherapy efficacy (7). For in-
stance, recent reports on preclinical models of cancer cachexia
have shown that quercetin and an immunomodulatory diet
(also enriched with antioxidant compounds such as vitamins
A, C, E, and zinc and selenium) positively affect muscle mass
in ApcMin/+ and C26-bearing mice, respectively (86, 142).
A beneficial action has been also achieved by resveratrol,
although the effectiveness has been proven only in C26 hosts
and not in other cachexia models, such as LLC or Yoshida
AH-130-bearing animals (20, 121). Conversely, a report by
Assi et al. has shown that the supplementation of a mixture of
antioxidants increases tumor growth in C26 hosts, worsening
muscle wasting and oxidative stress (6). On the same line, the
maintenance of stable circulating antioxidant vitamins and
b-carotene concentration seems to increase cancer patient
mortality (7). In addition, the administration of antioxidants
to cancer patients should be carefully evaluated when com-
bined with exercise, since several lines of evidence suggest
that antioxidants may hamper the beneficial adaptations of
chronic exercise in the skeletal muscle (52).
Despite directly administering antioxidants, oxidative
stress may also be targeted with compounds able to modulate
the ROS/RNS-regulated pathways, to reduce inflammation or
inhibit ROS-producing enzymes (Fig. 6). Using such an ap-
proach, different classes of drugs have been proven effective
in reverting cancer-induced muscle wasting by mimicking
some of the beneficial effects induced by exercise (11). No-
tably, trimetazidine (TMZ) increases muscle cross-sectional
area and strength in C26-bearing mice, coupled with in-
creased oxidative metabolism and mitochondrial mass (78).
These improvements could also rely on the modulation of the
redox balance.
FIG. 5. Exercise modu-
lates the oxidative stress
counteracting cancer- and
chemotherapy-induced mus-
cle atrophy. Cancer and
chemotherapy harm the





lead to increased expression of
genes involved in autophagy,
proteasome-dependent degra-
dation, and inflammation and
in further production of ROS
by dysfunctional mitochon-
dria. Conversely, exercise may
counteract these alterations by
reducing inflammation and in-
creasing mitochondrial func-
tion, in part, through PGC-1a
induction, the latter also con-
tributing to reinforce the anti-
oxidant defenses.




















































Notably, TMZ reduces the levels of markers of oxidative
stress and increases SOD activity in human aortic smooth
muscle cells (152) and decreases MDA levels in blood
sample from young and aged rats (151). In this regard, one
mechanism by which TMZ may modulate the redox balance
is the inhibition of the b-oxidation (45), thus favoring glucose
metabolism and reducing ROS production. Similarly to
TMZ, EPO has been shown to improve mitochondrial func-
tion and oxidative stress. Indeed, in human cardiomyocytes,
EPO contributes to correct doxorubicin-induced alterations
by upregulating SIRT1, inducing the activation of PGC-1a
and the transcription of genes involved in mitochondrial
homeostasis and antioxidant defenses (31). Consistently,
EPO-treated tumor-bearing mice show increased muscle
expression of PGC-1a, mitochondrial function, and ATP in-
tracellular levels (99).
Along with these drugs, molecules that are able to block or
reduce the activation of inflammatory pathways could be useful
to correct muscle oxidative stress. In a recent report by Hentilä
et al., the blockade of activin receptor type 2 (ACVR2) ligands
(e.g., myostatin, activins, and TGFb) by the recombinant sol-
uble activin receptor 2B (sACVR2B-Fc) has been proven to
modulate the redox balance in healthy and tumor-bearing an-
imals (57). In the latter, sACVR2B-Fc protects against muscle
wasting, increasing survival and correcting GSH reduction and
GSSG/GSH ratio increase (57, 87). Along with these effects,
the soluble activin receptor increases the expression of heat
shock protein 25 (HSP25) (57), which is involved in glutathi-
one metabolism and resistance to ROS (43).
An adaptive response to oxidative stress is also induced by
formoterol, a b2-adrenoceptor-selective agonist. Several
studies report the beneficial effects of this compound in re-
verting cancer-induced muscle wasting in both animal
models and cancer patients by triggering protein metabolism
toward synthesis and reducing inflammation (53, 92, 114,
136, 137). Along with the anabolic/anticatabolic effects,
formoterol also prevents the increase of oxidized proteins and
MDA/HNE-protein adducts in the skeletal muscle of Yoshida
AH-130-bearing rats (115). However, formoterol does not
increase SOD1 and catalase protein levels in tumor hosts
(115), suggesting that the mechanism by which this molecule
acts on oxidative stress does not rely on the induction of the
antioxidant defenses or, at least, the antioxidant induction is
not detectable at the experimental time point considered by
the authors. Conversely, formoterol could affect oxidative
stress indirectly by reducing inflammation, as suggested by
the decrease of inflammatory cell infiltration in the muscles
of tumor hosts (115).
Another strategy to reduce oxidative stress is the direct
targeting of enzymes responsible for ROS production.
Among them, xanthine oxidoreductase (XOR) is an intra-
cellular enzyme involved in purine catabolism that may exist
in two different forms, xanthine dehydrogenase or xanthine
oxidase (XO) (37). The latter is induced by stress conditions
(e.g., inflammation) and uses molecular oxygen as an electron
acceptor, producing superoxide anion and oxygen peroxide
(37). Notably, XO activity increases in unloading-induced
muscle atrophy and in the skeletal muscle of cachectic animals
(35, 129). In this regard, the inhibition of XO by allopurinol
prevents muscle and plasma XO activity and these effects
associate with the reduction of the oxidative stress-induced
protein p38 and atrogin-1, relieving unloading-induced muscle
atrophy (35).
Similarly, in Yoshida AH-130-bearing animals, the inhi-
bition of XO by allopurinol and oxypurinol partially pre-
vents body and muscle wasting and increases survival,
although the effects of oxypurinol vary depending on the
dosage (129). The macroscopic improvements associated
with the protection against several tumor-induced molecu-
lar alterations, such as increased inflammation, muscle protein
carbonylation, markers of proteasome activation, and pro-
teasome activity (129). Moreover, oxypurinol also improves
cardiac mass and function in cachectic tumor hosts (128).
However, particular attention should be given to tumor re-
sponse, since oxypurinol administration increases the tumor
mass in immunocompromised mice injected with MAC16
cells (140).
A final approach aimed at targeting the oxidative stress in
experimental cancer cachexia is the use of inhibitors of the
renin/angiotensin system (RAS). Beyond regulating blood
FIG. 6. Potential impact
of oxidative stress modula-
tors for correcting muscle
wasting. Molecules that act
on the redox balance in a
distinct manner, reducing in-
flammation, blocking XO
activity or the RAS, and in-
ducing PGC-1a expression/
activation, may preserve mus-
cle mass and function affected
by both cancer and chemo-
therapy. The most studied
molecules regulating muscle
oxidative stress in cancer ca-
chexia are presented close to
the mechanisms of action.
RAS, renin/angiotensin sys-
tem; XO, xanthine oxidase.




















































pressure, this system is also locally active in different tissues,
including the skeletal muscle. In this regard, the inhibition of
the angiotensin converting enzyme (ACE) with perindopril
prevents body wasting and muscle dysfunction, coupled with
increased succinate dehydrogenase activity in C26 hosts with
mild cachexia (82). Similarly, another RAS inhibitor spe-
cifically targeting renin, namely aliskiren, has proven effec-
tive in reverting muscle wasting in C26-bearing mice (145).
In this regard, aliskiren increases gastrocnemius muscle mass
and muscle function and decreases the levels of proin-
flammatory cytokines, of markers of autophagy, and of
atrogin-1 and MuRF-1 (145). These effects associate with
increased muscle SOD and GPX activity and with reduced
MDA and hydroxyl radical levels (145). However, it is
noteworthy that aliskiren also reduces tumor growth (145), so
making it difficult to distinguish if the drug has a direct effect
on the muscle or, by reducing tumor burden, indirectly im-
proves cachexia. Similarly, the abovementioned drug peri-
ndopril is able to decrease tumor mass in severely cachectic
C26 hosts (82).
Conclusions
Oxidative stress can be considered one of the most relevant
triggers of muscle wasting in cancer cachexia, acting at the
critical intersection between inflammation and mitochondrial
dysfunction. Thus, it is likely that cancer patients experi-
encing cachexia might benefit from an intervention aimed at
counteracting the excessive oxidative stress.
A desirable strategy to be set up should reinforce the
muscle antioxidant defenses of cancer patients by means of
exercise or exercise mimetic drugs rather than directly ad-
ministering antioxidants. Such a strategy would maximize
the beneficial aspects of oxidative stress control while min-
imizing the potentially detrimental action of antioxidants on
host adaptive responses and tumor growth.
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FJ. Cancer cachexia: understanding the molecular basis.
Nat Rev Cancer 14: 754–762, 2014.
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ACVR2¼ activin receptor type 2
AP-1¼ activator protein-1
BAT¼ brown adipose tissue








Nrf¼ nuclear respiratory factor




REE¼ resting energy expenditure
RNS¼ reactive nitrogen species
ROS¼ reactive oxygen species
RyR¼ ryanodine receptor
sACVR2B-Fc¼ soluble activin receptor 2B
SOD¼ superoxide dismutase
TGF¼ transforming growth factor
TMZ¼ trimetazidine
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